Elucida Oncology to Present at Two Upcoming Investor Conferences
MONMOUTH JUNCTION, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that Geno Germano, CEO and President of Elucida Oncology, and Ian Somaiya, CFO and CBO of Elucida Oncology, will present at two upcoming virtual investor conferences:
- MONMOUTH JUNCTION, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that Geno Germano, CEO and President of Elucida Oncology, and Ian Somaiya, CFO and CBO of Elucida Oncology, will present at two upcoming virtual investor conferences:
Mr. Germano will provide an overview of key upcoming milestones and give a corporate update on Elucida Oncologys novel ultra-small CDot drug delivery platform, with its lead program, ELU001, in Phase a 1/2 trial in patients with solid tumors overexpressing folate receptor alpha (FRa). - A live webcast of the J.P. Morgan Healthcare conference presentation will be available to attendees via the conference portal.
- Elucida Oncology, Inc., is a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy with its first-in-class, ultra-small nanoparticle CDot drug conjugate (CDC) platform.
- CDCs are designed to penetrate deeper into tumors and deliver a significantly higher payload compared to antibody drug conjugates (ADCs).